Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.35 -21.9%	$0.67	$0.35 ▼ $3.00	$2.77M	1.18	1.17 million shs	1.79 million shs
GOVX GeoVax Labs	$1.03 -9.6%	$1.00	$0.73 ▼ $11.18	$15.65M	3.45	515,656 shs	209,637 shs
LEXX Lexaria Bioscience	$0.98 -4.3%	$1.16	$0.92 ▼ $4.38	$17.15M	0.84	150,427 shs	88,662 shs
LPCN Lipocine	$3.12 -1.3%	$3.27	$2.68 ▼ $11.79	$16.69M	1.34	36,855 shs	12,166 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	-38.78%	-46.95%	-49.55%	-72.65%
GOVX GeoVax Labs	0.00%	-8.04%	+13.49%	-33.12%	-30.56%
LEXX Lexaria Bioscience	0.00%	-0.86%	-5.19%	-27.67%	-69.86%
LPCN Lipocine	0.00%	-0.64%	-16.35%	-6.87%	-60.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	3.2199 of 5 stars	3.8	5.0	2.2	0.0	1.3
GOVX GeoVax Labs	3.3798 of 5 stars	3.6	4.0	2.5	1.7	1.3
LEXX Lexaria Bioscience	2.5055 of 5 stars	3.5	2.0	3.0	1.7	0.6
LPCN Lipocine	2.1434 of 5 stars	3.5	3.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	2,185.06% Upside
GOVX GeoVax Labs	3.29	Buy	$11.10	977.67% Upside
LEXX Lexaria Bioscience	3.00	Buy	$7.00	616.85% Upside
LPCN Lipocine	3.00	Buy	$9.00	188.46% Upside

Current Analyst Ratings Breakdown

Latest ADIL, LPCN, GOVX, and LEXX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/2/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $9.00
4/16/2025	GOVX GeoVax Labs	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/15/2025	GOVX GeoVax Labs	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $8.50
4/10/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
3/28/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
GOVX GeoVax Labs	$5.59M	2.80	N/A	N/A	$3.24 per share	0.32
LEXX Lexaria Bioscience	$525.92K	32.60	N/A	N/A	$0.48 per share	2.03
LPCN Lipocine	$3.67M	4.54	N/A	N/A	$3.83 per share	0.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$1.46	N/A	N/A	N/A	N/A	-168.25%	-148.46%	8/12/2025 (Estimated)
GOVX GeoVax Labs	-$25.97M	-$3.65	N/A	N/A	N/A	N/A	-809.87%	-349.34%	8/5/2025 (Estimated)
LEXX Lexaria Bioscience	-$5.80M	-$0.59	N/A	N/A	N/A	-1,473.04%	-88.88%	-83.59%	7/11/2025 (Estimated)
LPCN Lipocine	-$16.35M	-$1.02	N/A	∞	N/A	N/A	-19.17%	-17.60%	8/6/2025 (Estimated)

Latest ADIL, LPCN, GOVX, and LEXX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/11/2025	N/A	LEXX Lexaria Bioscience	-$0.15	N/A	N/A	N/A	$0.17 million	N/A
5/14/2025	Q1 2025	ADIL Adial Pharmaceuticals	-$0.50	-$0.34	+$0.16	-$0.34	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million
5/1/2025	Q1 2025	GOVX GeoVax Labs	-$0.59	-$0.45	+$0.14	-$0.45	$0.75 million	$1.64 million
4/14/2025	Q2 2025	LEXX Lexaria Bioscience	-$0.16	-$0.15	+$0.01	-$0.15	$0.14 million	$0.17 million
3/27/2025	Q4 2024	GOVX GeoVax Labs	-$0.79	-$0.30	+$0.49	-$0.30	$2.38 million	$3.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
LEXX Lexaria Bioscience	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	6.78	6.78
GOVX GeoVax Labs	N/A	4.17	4.17
LEXX Lexaria Bioscience	N/A	29.62	29.62
LPCN Lipocine	N/A	12.97	12.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
GOVX GeoVax Labs	6.09%
LEXX Lexaria Bioscience	13.06%
LPCN Lipocine	9.11%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	5.24%
GOVX GeoVax Labs	1.20%
LEXX Lexaria Bioscience	26.40%
LPCN Lipocine	6.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	7.90 million	6.07 million	No Data
GOVX GeoVax Labs	10	15.19 million	8.90 million	Not Optionable
LEXX Lexaria Bioscience	7	17.56 million	12.92 million	Not Optionable
LPCN Lipocine	10	5.35 million	5.02 million	No Data

ADIL, LPCN, GOVX, and LEXX Headlines

Recent News About These Companies

Q1 Earnings Estimate for Lipocine Issued By HC Wainwright

June 13 at 2:17 AM | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for Lipocine (NASDAQ:LPCN)

June 12 at 1:19 AM | americanbankingnews.com

Lipocine (NASDAQ:LPCN) Stock Passes Below 200 Day Moving Average - Should You Sell?

June 10, 2025 | americanbankingnews.com

Le partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oral

June 9, 2025 | fr.investing.com

Lipocine annonce le dépôt d'une demande d'autorisation de mise sur le marché pour TLANDO au Canada

June 9, 2025 | zonebourse.com

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

June 9, 2025 | prnewswire.com

Le LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de Hepatology

May 23, 2025 | zonebourse.com

Lipocine’s LPCN 1148 Gains Fast Track Designation

May 22, 2025 | tipranks.com

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025 | prnewswire.com

Lipocine to Present at A.G.P. Healthcare Showcase

May 14, 2025 | tipranks.com

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025 | prnewswire.com

Lipocine Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025 | prnewswire.com

Lipocine inks license and supply agreement for TLANDO in Brazil

May 7, 2025 | msn.com

Lipocine s’associe à Aché pour commercialiser TLANDO au Brésil

May 7, 2025 | fr.investing.com

Lipocine Inc. annonce un accord de licence et d'approvisionnement pour Tlando® au Brésil

May 7, 2025 | zonebourse.com

Lipocine Partners with Aché for TLANDO® in Brazil

May 6, 2025 | tipranks.com

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025 | prnewswire.com

L’action LPCN atteint son plus bas niveau sur 52 semaines à 2,91$

April 7, 2025 | fr.investing.com

Lipocine Inc. Reports 2024 Financial Turnaround

April 4, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL, LPCN, GOVX, and LEXX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.35 -0.10 (-21.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.35 0.00 (-0.03%)

As of 06/13/2025 07:57 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

GeoVax Labs NASDAQ:GOVX

$1.03 -0.11 (-9.65%)

As of 06/13/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Lexaria Bioscience NASDAQ:LEXX

$0.98 -0.04 (-4.26%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.99 +0.01 (+1.38%)

As of 06/13/2025 07:51 PM Eastern

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Lipocine NASDAQ:LPCN

$3.12 -0.04 (-1.27%)

Closing price 06/13/2025 03:52 PM Eastern

Extended Trading

$3.14 +0.02 (+0.61%)

As of 06/13/2025 07:03 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time